

Impact of direct-acting antiviral treatment of hepatitis C on the quality of life of adults in Ukraine

Benade M^{1*}, Rosen S^{1,2}, Antoniak S³, Chasela C^{4,5}, Stopolianska Y³, Barnard T⁶, Gandhi MM⁷, Ivanchuk I⁸, Tretiakov V⁹, Dible J⁶, Minior T⁶, Chew KW⁷, van der Horst C^{10†}, Tsenilova Z¹¹, Sanne I^{2,4,12}, for EQUIP Health**

Affiliation

1. Boston University School of Public Health, Boston, MA USA
2. Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
3. Right to Care, Kyiv, Ukraine
4. Right to Care, Centurion, Pretoria, South Africa
5. Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
6. United States Agency for International Development, DC, USA
7. David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
8. Public Health Centre of Ministry of Healthcare of Ukraine
9. 100% Life, Kyiv, Ukraine
10. University of North Carolina, Chapel Hill, NC USA
11. Alliance for Public Health, Kyiv, Ukraine
12. Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

*Corresponding author: mbenade@bu.edu

†Deceased

**EQUIP is a consortium of African non-governmental organizations and international partners that was sponsored by USAID to assist countries through innovations to meet the UNAIDS 90-90-90 targets

Word count: 1,798/1800

29 **Abstract (249/250)**

30 **Background**

31 Direct-acting antivirals (DAAs) are highly effective in achieving sustained virologic response among those with chronic hepatitis C virus (HCV)
32 infection. Quality of life (QOL) benefits for an HCV-infected population with high numbers of people who inject drugs and people living with
33 HIV (PLHIV) in Eastern Europe have not been explored. We estimated such benefits for Ukraine.

34 **Methods**

35 Using data from a demonstration study of 12-week DAA conducted in Kyiv, we compared self-reported QOL as captured with the MOS-SF20 at
36 study entry and 12 weeks after treatment completion (week 24). We calculated domain scores for health perception, physical, role and social
37 functioning, mental health and pain to at entry and week 24, stratified by HIV status.

38 **Results**

39 Among the 857 patients included for the final analysis, health perception was the domain that showed the largest change, with an improvement of
40 85.7% between entry and week 24. The improvement was larger among those who were HIV negative (104.4%) compared to those living with
41 HIV (69.9%). Other domains that showed significant and meaningful improvements were physical functioning, which improved from 80.5 (95%
42 CI: 78.9-82.1) at study entry to 89.4 (88.1-90.7) at 24 weeks, role functioning (64.5 [62.3-66.8] to 86.5 [84.9-88.2], social functioning (74.2 [72.1-
43 76.2] to 84.8 [83.2-86.5] and bodily pain (70.1 [68.2-72.0] to 89.8 [88.5-91.1]). Across all domains, QOL improvements among PLHIV were more
44 modest than among HIV-negative participants.

45 **Conclusion**

46 QOL improved substantially across all domains between study entry and week 24. Changes over the study period were smaller among PLHIV.

47

48 Key words: HCV, HIV, Treatment, PWID, Ukraine, Quality of Life

49 **Background**

50 Viral hepatitis C infection (HCV) remains a major public health concern globally, with 71 million people estimated to be living with chronic HCV
51 infection and at high risk of developing liver cirrhosis, hepatocellular carcinoma, liver failure, and death if left untreated.¹⁻³ DAA treatment, which
52 cures HCV within 8-12 weeks, is now widely available in some countries.⁴ Benefits in treating HCV are found in averted deaths, reduced
53 morbidity, and improvement of reported QOL and economic productivity.⁵⁻⁸

54

55 In Ukraine, it is estimated that 3.5% of the general population are living with HCV, of whom a large proportion are people who inject drugs
56 (PWID) and many are co-infected with HIV.⁹ Other high risk groups include sexual partners of those with HIV, sex workers, prisoners, military
57 members, and populations in conflict zones.⁹ Lack of adequate state funding, especially for diagnostics, presents a significant barrier to accessing
58 treatment with DAA.¹⁰

59

60 In 2018, a single-arm demonstration project was implemented to evaluate a scalable, integrated, low cost HIV and HCV testing and management
61 intervention in Ukraine offering HCV treatment with sofosbuvir/ledipasvir for 12 weeks, with or without weight-based ribavirin (WBR) in
62 Ukraine.¹¹ The study also collected data on participants' self-reported QOL at the start and end of the study period, which we present here.

63

64 **Methods**

65 *Parent study*

66 For the original demonstration study, patients were enrolled at two public clinics in Kyiv, Ukraine. Study sites, sample selection and data
67 collection have been described previously.¹¹ Eligibility criteria included HCV viraemia, being treatment naïve and age ≥ 18 years, and no or
68 compensated liver cirrhosis. Those eligible were offered HIV and HCV testing, 12-week treatment of HCV with DAAs supported by simplified
69 HCV treatment monitoring, and initiation of HIV antiretroviral therapy (ART) for those with untreated HIV co-infection. The study's primary
70 outcome was sustained virologic response (SVR) at 12 weeks post treatment completion (24 weeks). Of the 868 participants enrolled, 860
71 completed the 24-week follow-up visit and were assessed for SVR. By intention-to-treat analysis, the overall treatment success rate was 95.7%
72 (831/868).¹¹

73

74 *Quality of life data and analysis*

75 Interviews were conducted at study entry and 24 weeks for QOL indicators, using an adapted version of the Medical Outcomes Study 20-Item
76 Short Form Health survey (MOS SF-20) (supplementary file 1).¹² We compared QOL measures between baseline and endline for each question.
77 We also aggregated responses according to MOS SF-20 categories of health perception, physical functioning, mental health, role functioning,
78 social functioning, and bodily pain to assign a mean value for each category at baseline and endline, stratified by HIV status. Scores for each of the
79 six subscales (physical, social and role functioning, pain, mental health, and health perception) were calculated as described by Stewart et al¹². In
80 each domain, the lowest possible score was zero and the highest possible score was 100. We stratified the domain scores by HIV status and
81 performed t-tests to determine statistical significance in difference of means between baseline and endline, as well as by HIV status and major
82 demographic characteristics (age, education, employment status, injection drug use status).

83

84

85 **Results**

86 Of the 868 patients who were included in the primary analysis, we assessed baseline data on all 868 and endline data on 857, with the discrepancy
87 reflecting patients who did not complete the study or had substantial missing data on QOL variables. Detailed characteristics of enrolled
88 participants, their clinical and laboratory outcomes, and the costs of the intervention to the provider are reported elsewhere¹¹ and summarized in
89 supplementary table 1. The median (IQR) age of the population was 39 years (35-44) and 66% were male. Most participants identified as PWID
90 (87%), of whom 95% self-reported being on medication-assisted therapy (MAT). Just over half the sample (482, 55%) were HIV positive; all were
91 on ART at the time of study enrollment. The 11 patients who were excluded from the final analysis did not differ from those in the analysis in
92 terms of employment status or education level; all those excluded identified as PWID; were younger than 45 years, did not have liver cirrhosis,
93 and were more likely to be co-infected with HIV; and 90% were male (supplementary table 2).

94
95 Responses to all QOL questions at baseline and endline are reported in supplementary table 3. Below we highlight differences between the two
96 periods in the six domains listed above.

97

98 *Self-reported health*

99 At study entry, 66% of participants reported their health as either “poor” or “fair”. By study exit, 80% reported their health as “good”, “very good”
100 or “excellent.” Consistent with this result, 73% of participants reported that their health was either “somewhat better” (43%) or “much better
101 (30%) at 24 weeks than at study entry. The proportion of patients who agreed with the statement “my health is excellent” increased from 27% to

102 68% over the study period, while those agreeing with the statement “I have been feeling bad lately” decreased from 57% to 11%. The mean
103 domain score for health perception increased from 33.7 (95% CI 32.4-35.1) at study entry to 62.3 (60.7-63.9) at 24 weeks (Figure 1).

104

105 *Physical activities, role, and social functioning*

106 The proportions of participants who reported being limited in conducting a range of physical activities fell over the study period for all activities
107 (Figure 2). The largest difference was seen in vigorous activity, where the proportion who reported facing limitations declined from 54% to 32%.
108 The mean domain score for physical functioning increased from 80.5 (95% CI 78.9-82.1) to 89.4 (88.1-90.7). Formal sector employment also rose
109 over the study period, from 33% to 40% of the cohort. The proportion of participants who reported that their health affected “a lot” the quality at
110 which they could perform their main activity decreased from 76% at study entry to 12% at 24 weeks. The mean number of days that participants
111 were unable to perform their main activity due to their health or seeking health care in the past 2 weeks decreased from 1.6 (95% CI 1.5-1.8) days
112 to 0.8 (0.6-1.0) days over the study period. Finally, the mean social functioning score improved from 74.2 (95% CI 72.1-84.8) to 84.8 (83.2-86.5).

113

114 *Mental health and symptoms*

115 Questions related to anxiety and depression showed a substantial improvement in mental health over the study period (Figure 2), with the mean
116 score for the mental health domain increasing from 67.0 (95% CI 65.5-68.2) to 70.5 (69.1-66.9).

117

118 The proportion of patients who reported having no or very mild inability to focus increased from 54% at study entry to 77% at endline, while those
119 who reported a moderate inability to focus decreased from 23% to 9%. An improvement in reported tiredness and fatigue was also observed,

120 increasing from 21% who reported no or very mild fatigue at study entry to 62% at 24 weeks. Bodily pain improved from 50% reporting no or
121 very mild body pain at initiation to 84% at study endline. The mean domain score for pain improved from 70.1 (95% CI 68.2-72.0) to 89.8 (88.5-
122 91.1) over the study period.

123

124 *Stratification by HIV status*

125 Participants with HIV and those without did not differ at baseline for any of the domains (supplementary table 3). Domain scores reported at 24
126 weeks in the physical functioning domain were lower for PLHIV (87.4, 95% CI 85.5-89.4) than for those not living with HIV (91.9, 90.0-93.5).
127 Improvements in the social domain were larger among those who were not living with HIV (87.7, 95% CI 85.5-89.9) than among those with HIV
128 (82.5, 80.1-84.9). Similarly, health perception improved by a larger margin among those who were not living with HIV (67.9, 95% CI 64.5-70.3)
129 than among those with HIV (57.7, 55.6-59.9). Role functioning was slightly higher among those not living with HIV (87.2 (95% CI 84.7-89.8) vs
130 85.8 (83.5-88.1)) and domain scores for pain and mental health were marginally higher among PLHIV, but these differences were not statistically
131 significant.

132

133 Other variables such as education, age, employment status and whether or not participant was considered PWID were also examined but there
134 were no differences in these indicators between people with and without HIV.

135

136

137

138 Discussion

139 In this study of more than 850 HCV-infected adults in Ukraine, of whom most were PWID and over half had HIV, effective HCV treatment
140 produced large gains in QOL across all measured domains. The greatest improvements between study enrollment (baseline) and 24 weeks
141 (endline) were in health perception (+26.8), role functioning (+22.0), and pain (+19.7). Social functioning (+10.9) and physical functioning (+8.9)
142 improved somewhat less but still showed significant improvement at endline compared to study entry.

143
144 The results we observed in this cohort in Ukraine were similar to or of greater magnitude than those reported from other settings.^{5,13-15} In a
145 Japanese cohort, the only domain of the MOS SF-36 that was found to be significantly improved was general health perception, with an
146 improvement of 3.81 that persisted at 3 years after treatment with DAA.⁵ Younossi et al found similarly that statistically significant, modest
147 improvements in reported QOL were sustained as long as 2 years after SVR was achieved in U.S. patients.¹⁶ The larger improvements we
148 observed may reflect our relatively short follow up period (24 weeks after treatment initiation) and the fact that our study was conducted in a
149 middle income country, rather than high income, and among many patients with co-morbidities; our participants had worse baseline domain scores
150 and thus more room for HCV treatment to improve their QOL.

151
152 Our study had several limitations. Data were drawn from a single-arm implementation trial; we had no HCV-negative comparison population.
153 Because the treatment success rate was so high, we also lack a comparison with those failing HCV treatment. It is possible that some of the
154 improvements we observed would have come about anyway, without HCV treatment, though the relatively short interval between our baseline and
155 endline interviews (24 weeks) makes major secular shifts unlikely. By definition, patients who were lost to follow up were missing endline data; if

156 these patients were also sicker or more disabled by HCV than were those who did finish, our results would overestimate overall improvements.
157 Comparison of the two groups at baseline, however, did not reveal any differences in their condition. Our choice of tool, the SF-20, is known to
158 have floor effects for social functioning, bodily pain, and role functioning and ceiling effects across all domains reported. Finally, our endline
159 measurement took place 12 weeks after treatment completion, and therefore findings are limited to short-term improvements in QOL only.

160

161 Despite these limitations, the large improvements we observed in QOL for this cohort of patients suggests that HCV treatment, as delivered in this
162 intervention, has a major positive effect on the mental and physical well-being, self-perception, and productivity of those who complete treatment.
163 While some of the impacts are slightly more modest for patients with HIV, general conclusions remain the same. These results add to the benefits
164 of offering effective HCV treatment to all with active HCV infection.

165 **Funding**

166 This work was supported by USAID EQUIP Grant No. AID-OAA-A-1500070 to Right to Care and Luxemburg Business Partnership Facility
167 2017, Grant No. MAE/014 – 17 1620.

168 **Competing interests**

169 KWC has received a research grant to the institution from Merck Sharpe & Dohme. The remaining authors declare that they have no competing
170 interests.

171

172 **Authors' contributions**

173 IS, SR, CC, KWC, CVDH, TB, SA, conceived the study; SA, YS, TB, II conducted the study; MB, SR, CC, KWC, MMG analyzed the data; MB,
174 SR drafted the manuscript; all authors reviewed and approved the final manuscript.

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206

207 **References**


- 208
209 1. World Health Organization (WHO). *Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections 2019. Accountability for*
210 *the Global Health Sector Strategies, 2016–2021*. Geneva: World Health Organization; 2019 (WHO/CDS/HIV/19.7). Licence: CC BY-NC-


- 211 SA 3.0 IGO. Accessed March 16, 2021. moz-extension://77d9bcb3-06d9-474a-ae6b-2822763c4b12/enhanced-
 212 reader.html?openApp&pdf=https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F324797%2FWHO-CDS-HIV-
 213 19.7-eng.pdf
- 214 2. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. *Hepatology*. 2015;61(1):77-
 215 87. doi:10.1002/hep.27259
 - 216 3. Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. *Lancet*. 2019;394(10207):1451-1466. doi:10.1016/S0140-
 217 6736(19)32320-7
 - 218 4. Carrat F, Fontaine H, Dorival C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a
 219 prospective cohort study. *Lancet*. 2019;393(10179):1453-1464. doi:10.1016/S0140-6736(18)32111-1
 - 220 5. Ichikawa T, Miyaaki H, Miuma S, et al. Direct-Acting antivirals improved the quality of life, ameliorated disease-related symptoms, and
 221 augmented muscle volume three years later in patients with hepatitis C Virus. *Intern Med*. 2020;59(21):2653-2660.
 222 doi:10.2169/internalmedicine.5102-20
 - 223 6. Nardelli S, Riggio O, Rosati D, Gioia S, Ridola L, Farcomeni A. Hepatitis C virus eradication with directly acting antivirals improves
 224 health-related quality of life and psychological symptoms. *World J Gastroenterol*. 2019;25(48):6928-6938. doi:10.3748/wjg.v25.i48.6928
 - 225 7. Fagundes RN, de Castro Ferreira LEVV, de Lima Pace FH. Health-related quality of life and fatigue in patients with chronic hepatitis C
 226 with therapy with direct-acting antivirals agents interferon-free. *PLoS One*. 2020;15(8 August). doi:10.1371/journal.pone.0237005
 - 227 8. Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: A systematic review of the clinical, economic
 228 and quality of life benefits. *BMC Infect Dis*. 2015;15(1):1-19. doi:10.1186/s12879-015-0748-8
 - 229 9. Devi S. Ukrainian health authorities adopt hepatitis C project. *Lancet (London, England)*. 2020;396(10246):228. doi:10.1016/S0140-
 230 6736(20)31639-1
 - 231 10. Health TA for P. Over 5% of Ukrainians are infected with hepatitis C. Published 2016. Accessed March 16, 2021.
 232 <https://aph.org.ua/en/news/over-5-of-ukrainians-are-infected-with-hepatitis-c/>
 - 233 11. Antoniak S, Charles Chasela C, Freiman MJ, et al. Treatment and Cost -outcomes of a simplified antiretroviral treatment strategy for
 234 hepatitis C among HCV and HIV co-infected patients in Ukraine. *medRxiv*. Published online January 1, 2021:2021.03.19.21253780.
 235 doi:10.1101/2021.03.19.21253780
 - 236 12. Stewart AL, Hays RD, Ware JE. *The MOS Short-Form General Health Survey: Reliability and Validity in a Patient Population*. Vol 26.;
 237 1988.
 - 238 13. Schulte B, Schmidt CS, Manthey J, et al. Clinical and patient-reported outcomes of direct-acting antivirals for the treatment of chronic
 239 hepatitis C among patients on opioid agonist treatment: A real-world prospective cohort study. *Open Forum Infect Dis*. 2020;7(8).
 240 doi:10.1093/ofid/ofaa317
 - 241 14. Thein H-H, Krahn M, Kaldor J. Estimation of Utilities for Chronic Hepatitis C from SF-36 Scores Health Policy Gap Analysis View
 242 project Ethical aspects of infectious disease control View project. *Artic Am J Gastroenterol*. Published online 2005. doi:10.1111/j.1572-
 243 0241.2005.40976.x
 - 244 15. Serper M, Evon DM, Amador J, et al. Patient-Reported Outcomes 12 Months After Hepatitis C Treatment with Direct-Acting Antivirals:
 245 Results from the PROP UP Study. *Liver Int*. Published online January 2, 2021. doi:10.1111/liv.14781
 - 246 16. Younossi ZM, Racila A, Muir A, et al. Long-Term Patient Centered Outcomes in Cirrhotic Patients with Chronic Hepatitis C After

247 Achieving Sustained Virologic Response. *Clin Gastroenterol Hepatol.* 2021;0(0). doi:10.1016/j.cgh.2021.01.026

248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276


277 **Figure 1. Self-reported health at study entry (baseline) and 24 weeks**





284
285
286
287
288

289 **Figure 2.** Functional impairment at study entry (baseline) and 24 weeks
290
291 Response to the question, “My health limits me in doing the following activities...”



292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311